Zacks Research Has Bearish Estimate for SBC Q3 Earnings

Key Points

• Zacks Research cut SBC Medical Group’s Q3 2026 EPS estimate to $0.10 from $0.13 and forecast Q4 EPS at $0.10, signaling a more cautious near-term earnings outlook.
• SBC’s latest quarter produced $0.10 EPS, missing the $0.12 consensus, although revenue of $49.19 million exceeded expectations of $45.37 million.
• Analyst sentiment remains mixed: the stock has a consensus “Hold” rating with an average price target of $8.50, while shares recently opened at $3.87 and institutional investors own 60.82% of the company.

SBC Medical Group Holdings Incorporated (NASDAQ:SBC - Free Report) - Stock analysts at Zacks Research decreased their Q3 2026 earnings estimates for SBC Medical Group in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst M. Marin now anticipates that the company will earn $0.10 per share for the quarter, down from their prior estimate of $0.13. The consensus estimate for SBC Medical Group's current full-year earnings is $0.48 per share. Zacks Research also issued estimates for SBC Medical Group's Q4 2026 earnings at $0.10 EPS.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.02). SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%.The firm had revenue of $49.19 million for the quarter, compared to the consensus estimate of $45.37 million.

SBC has been the subject of a number of other reports. Weiss Ratings lowered shares of SBC Medical Group from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, May 22nd. Wall Street Zen raised SBC Medical Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. Finally, BTIG Research reiterated a "buy" rating and issued a $8.00 price target on shares of SBC Medical Group in a research note on Thursday, August 13th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $8.50.

SBC Medical Group Stock Performance

Shares of SBC Medical Group stock opened at $3.87 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. SBC Medical Group has a 52 week low of $2.78 and a 52 week high of $5.07. The firm has a fifty day moving average of $3.12 and a two-hundred day moving average of $3.55. The stock has a market capitalization of $396.98 million, a price-to-earnings ratio of 8.23 and a beta of 0.59.

Hedge Funds Weigh In On SBC Medical Group

Several institutional investors have recently added to or reduced their stakes in SBC. BlackRock Inc. purchased a new stake in shares of SBC Medical Group in the 2nd quarter valued at about $2,846,000. Geode Capital Management LLC bought a new position in shares of SBC Medical Group in the second quarter worth approximately $455,000. Segall Bryant & Hamill LLC bought a new stake in shares of SBC Medical Group in the first quarter worth about $340,000. Millennium Management LLC bought a new stake in SBC Medical Group in the third quarter valued at $219,000. Finally, Bank of New York Mellon Corp purchased a new stake in SBC Medical Group in the second quarter worth about $83,000. Institutional investors own 60.82% of the company's stock.

Key SBC Medical Group News

Here are the key news stories impacting SBC Medical Group this week:

• Positive Sentiment: An analysis of SBC’s second-quarter 2026 results characterized the period as evidence of resumed growth, while the company continues implementing measures intended to support further expansion. This reinforces the recovery narrative for investors. SBC: 2Q26 results illustrate resumed growth, as growth measures continue
• Positive Sentiment: Sidoti raised its SBC earnings-per-share forecast for fiscal 2026 to $0.47 from $0.44, matching the broader consensus estimate. The firm also increased its fiscal 2027 forecast to $0.52 from $0.49, suggesting greater confidence in the company’s forward earnings trajectory. Sidoti raises SBC earnings estimates
• Positive Sentiment: Sidoti lifted its quarterly estimates for SBC, including Q3 and Q4 2026 EPS to $0.12 from $0.11, Q1 2027 EPS to $0.12 from $0.11, and Q2 2027 EPS to $0.13 from $0.12. These revisions indicate expectations for steady profitability through the next several quarters. Sidoti quarterly earnings estimate revisions
• Neutral Sentiment: A separate article contrasts SBC Medical Group with Henry Schein, but the headline does not identify a specific change to SBC’s earnings outlook, operations, or valuation. Consequently, it is unlikely to be a major standalone driver of the stock’s recent move. Contrasting Henry Schein and SBC Medical Group

SBC Medical Group Company Profile

SBC Medical Group, Inc is a publicly traded healthcare management services company listed on the Nasdaq under the ticker SBC. The company specializes in supporting in-office ancillary service providers by offering a suite of administrative and operational solutions designed to streamline practice management and enhance revenue performance. Its core mission is to help physician practices, imaging centers and other ancillary service providers focus on patient care while outsourcing complex back-office functions.

The company's primary offerings include revenue cycle management, medical billing and coding, compliance oversight and transcription services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source